Drug resistance in HCC treatment is one of the reasons for the poor prognosis of HCC patients, and its mechanisms include autocrine and paracrine LIF signaling, epigenetic regulation of TFR2, regulatory SLC7A11 transcription, and six2 overexpression [3–5]. This evidence concerns the gene LIF and hepatocellular carcinoma.